Regulus Therapeutics Inc.
(NASDAQ CM: RGLS)
Rigrodsky Law, P.A. is investigating Regulus Therapeutics Inc. (“Regulus”) regarding possible breaches of fiduciary duties and other violations of law related to Regulus’ agreement to be acquired by Novartis AG. Under the terms of the agreement, Regulus shareholders will receive $7.00 per share in cash.